Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Nubeqa® (darolutamide) – Expanded indication
June 3, 2025 - The FDA announced the approval of Bayer’s Nubeqa (darolutamide), for the treatment of adult patients with metastatic castration-sensitive prostate cancer (mCSPC).
